|
Dr. Chang H. Ahn is an internationally recognized drug development expert with over 20 years of experience in the fields of pharmacology and biotechnology. He founded Rexahn Corporation in 2001 and currently serves as the company's chairman and CEO. Prior to founding Rexahn Dr. Ahn held dual positions as both Expert Regulatory Officer and Lab Chief at the FDA's Center for Drug Evaluation and Research. While at the FDA Dr. Ahn represented the agency in the fields of Antisense Oligonucleotide Therapeutics and Multi-Drug Resistance and served a key role as both author and co-author of several FDA guidance documents. Before joining the FDA Dr. Ahn carried out cancer research at the National Cancer Institute and Emory University's School of Medicine. Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum of which Maryland State and Montgomery County are partners. He has also served as president of the Society of Biomedical Research since 2000. Dr. Ahn earned his Ph.D. in pharmacology at Ohio State University in 1985. He also holds two B.S. degrees in pharmacy from Creighton University and Seoul National University. | 